扩张性心肌病重度心衰患者的抗凝治疗分析

张韶辉,刘金伟,刘剑敏

中国药学杂志 ›› 2016, Vol. 51 ›› Issue (20) : 1800-1802.

PDF(465 KB)
PDF(465 KB)
中国药学杂志 ›› 2016, Vol. 51 ›› Issue (20) : 1800-1802. DOI: 10.11669/cpj.2016.20.017
论著

扩张性心肌病重度心衰患者的抗凝治疗分析

  • 张韶辉,刘金伟,刘剑敏
作者信息 +

Management of Anticoagulation Therapy in One Patient with Dilated Cardiomyopathy and Severe Heart Failure

  • ZHANG Shao-hui, LIU Jin-wei, LIU Jian-min
Author information +
文章历史 +

摘要

目的 评价1例扩张性心肌病重度心衰患者的抗凝治疗方案。方法 查阅文献及指南,综述窦性心律重度心衰患者抗凝处理方案。结果 临床药师参与药物治疗,制定合理的抗凝治疗方案。结论 应充分评估重度心衰患者的心脑血管事件风险及出血风险,个体化制定抗凝治疗策略。

Abstract

OBJECTIVE To evaluate the anticoagulation therapy regimen in one patient with dilated cardiomyopathy and severe heart failure. METHODS Literatures and clinical practice guidelines were consulted, referring to the management of anticoagulation therapy in heart failure with sinus rhythm. RESULTS Clinical pharmacist participated in the process of drug treatment and decided on optimal anticoagulation therapy. CONCLUSION Individual bleeding and thrombotic risk should be evaluated to optimize the treatment of individual patients with heart failure.

关键词

扩张性心肌病 / 心力衰竭 / 抗凝

Key words

dilated cardiomyopathy / heart failure / anticoagulation

引用本文

导出引用
张韶辉,刘金伟,刘剑敏. 扩张性心肌病重度心衰患者的抗凝治疗分析[J]. 中国药学杂志, 2016, 51(20): 1800-1802 https://doi.org/10.11669/cpj.2016.20.017
ZHANG Shao-hui, LIU Jin-wei, LIU Jian-min. Management of Anticoagulation Therapy in One Patient with Dilated Cardiomyopathy and Severe Heart Failure[J]. Chinese Pharmaceutical Journal, 2016, 51(20): 1800-1802 https://doi.org/10.11669/cpj.2016.20.017
中图分类号: R969.3   

参考文献

SAMAMA M M. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med, 2000, 160(22):3415-3420.
SHAROUNI E, BRADSHAW A, ANEREOTI F, et al. Relationship between hemostatic abnormaltities and neuroendecrine activity in heart failure. Am Heart J, 1994, 127(3):607-612.
LOH E, SUTTON M S, WUN C C, et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med, 1997, 336(336):251-257.
ABDUL-RAHIM A H, PEREZ A C, FULTON R L, et al. Risk of stroke in chronic heart failure patients without atrial fibrillation:analysis of the CORONA and GISSI-HF trials. Circulation, 2015,131(17):1468-1494.
CLELAND J G, FINDLAY I, JAFRI S, et al. The warfarin/aspirin study in heart failure (wash):a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J, 2004, 148(1):157-164.
COKKINOS D V, HARALABOPOULOS G C, KOSTIS J B, et al. Efficacy of antithrombotic therapy in chronic heart failure:the helas study. Eur J Heart Fail, 2006, 8(4):428-432.
MASSIE B M, COLLINS J F, AMMON S E, et al. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure:the warfarin and antiplatelet therapy in chronic heart failure (watch) trial. Circulation, 2009, 119(12):1616-1624.
HOMMA S, THOMPSON J L P, SANFORD A R, et al. Benefit of warfarin compared with aspirin in patients with heart failure in sinus rhythm:a subgroup analysis of warcef, a randomized controlled trial. Circ Heart Fail, 2013, 6(5):988-997.
BAKALLI A, GEORGIEVSKA-ISMAIL L, KOCINAJ D, et al. Prevalence of left chamber cardiac thrombi in patients with dilated left ventricle at sinus rhythm:the role of transesophageal echocardiography. J Clin Ultrasound, 2013, 41(1):38-45.
PDF(465 KB)

Accesses

Citation

Detail

段落导航
相关文章

/